



an Open Access Journal by MDPI

State of the Art and Future Perspectives in Oncologic Imaging

Guest Editors:

Dr. Adrien Holzgreve

Department of Nuclear Medicine,
University Hospital, LMU Munich,
Munich, Germany

Dr. Lena M. Unterrainer

Department of Nuclear Medicine,
University Hospital, LMU Munich,
Munich, Germany

Prof. Dr. Wolfgang Kunz

Department of Radiology,
University Hospital, LMU Munich,
Munich, Germany

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

Imaging has a fundamental role in oncology. Staging studies are indispensable for selecting a therapy or making a prognosis. Hardly any tumor surgery or radiotherapy is performed without prior image-guided planning. Likewise, we depend heavily on imaging to assess response to therapy. However, in contrast to its long-standing tradition in oncology, imaging is also one of the most exciting and dynamic fields: due to the constant relevance of imaging in the course of the disease, imaging is an omnipresent companion that mirrors the rapid and groundbreaking developments in the field of oncology. On the other hand, developments in the field of oncologic imaging are a genuine contributor to advances in the treatment of cancer patients. Thus, response criteria are based on imaging and are constantly refined, new theranostic targets can be addressed with the advances in imaging (e.g., using hybrid imaging techniques such as PET/CT or PET/MRI), and artificial intelligence imaging methods broaden the horizon even more.

Therefore, we encourage the submission of articles both on state-of-the-art and future perspectives of oncologic imaging.

Kind regards,

Guest Editors



mdpi.com/si/124964



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)